Real world evidence market is growing fast

Applications of RWE-based insights range from drug discovery to supporting regulatory decision-making
Register for free to listen to this article
Listen with Speechify
0:00
2:00

LONDON—With the announcement from Roots Analysis that it has added the “Pharmaceutical and Life Sciences Real World Evidence Market, (2nd Edition), 2021-2030” report to its list of offerings come the highlights as well—and those suggest that real-world evidence (RWE) is gaining ground with the quickness.

As Roots Analysis notes, the digitization of data and advances in information processing have led to the development of a wide array of tools and analytical algorithms that can now be used to mine pharmaceutical big data. The insights generated from such studies are increasingly being used to drive important judgments concerning pharmacology and healthcare.

According to this recent report, the RWE market is projected to be worth $4.5 billion by 2030, at a compound annual growth rate (CAGR) of 15 percent.

Some of the key insights from the report include:

  • More than 100 global events related to RWE were organized in the past couple of years. Among the active industry players, Pfizer participated in most of these events (70), followed by Merck, Janssen, Sanofi, Amgen, Eli Lilly, GSK, and AstraZeneca. These events featured the participation of several non-industry players as well, which includes FDA, University of California, Harvard Medical School, and Stanford University.
  • Close to 2,200 articles on RWE have been published in reputable scientific journals since 2016. More than 20 percent of the publications noted were focused on generating or using RWE-based insights for the assessment of safety and efficacy of various medical products.
  • In the last 10 years, close to 1,600 clinical trials informed using RWE have been registered, The number of such trials has increased at a CAGR of 21 percent from 2010
  • The majority of these trials are focused on cardiovascular disorders, oncological disorders, and neurological disorders.

In modern healthcare, the applications of real world data-based insights are vast, ranging from drug discovery to supporting regulatory decision-making; in fact, the FDA routinely uses RWE monitor post market safety of drugs.

Related Topics

Published In

Volume 17 - Issue 4 | April 2021

April 2021

April 2021 issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue